NCCN Task Force Report: Oral chemotherapy.

Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy.

[1]  C. Earle,et al.  Does reimbursement influence chemotherapy treatment for cancer patients? , 2006, Health affairs.

[2]  E. Emanuel,et al.  Why well-insured patients should demand value-based insurance benefits. , 2007, JAMA.

[3]  F. Curtiss Pharmacy Benefit Spending on Oral Chemotherapy Drugs , 2006, Journal of managed care pharmacy : JMCP.

[4]  Peter J. Neumann,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[5]  J. Schellens Challenges of oral chemotherapy. , 2005, Clinical advances in hematology & oncology : H&O.

[6]  J. Taylor,et al.  Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia , 2006, Cancer.

[7]  Nandita Mitra,et al.  Patient online self-reporting of toxicity symptoms during chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Bruce S. Manheim,et al.  'Follow-on biologics': ensuring continued innovation in the biotechnology industry. , 2006, Health affairs.

[9]  David Artz,et al.  Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Schneeweiss,et al.  Adherence to Statin Therapy Under Drug Cost Sharing in Patients With and Without Acute Myocardial Infarction: A Population-Based Natural Experiment , 2007, Circulation.

[11]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[12]  D. Silk,et al.  Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. , 2006, Health affairs.

[13]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[15]  J. Tsang,et al.  Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Fendrick,et al.  Value-based insurance design: a "clinically sensitive" approach to preserve quality of care and contain costs. , 2006, The American journal of managed care.

[17]  S. Weingart,et al.  Oral chemotherapy safety practices at US cancer centres: questionnaire survey , 2007, BMJ : British Medical Journal.